126 related articles for article (PubMed ID: 17239590)
1. A quantitative assessment of hERG liability as a function of lipophilicity.
Waring MJ; Johnstone C
Bioorg Med Chem Lett; 2007 Mar; 17(6):1759-64. PubMed ID: 17239590
[TBL] [Abstract][Full Text] [Related]
2. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
3. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
[TBL] [Abstract][Full Text] [Related]
4. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
5. The interactions between hERG potassium channel and blockers.
Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
[TBL] [Abstract][Full Text] [Related]
6. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells.
Du X; Lu D; Daharsh ED; Yao A; Dewoody R; Yao JA
J Pharmacol Toxicol Methods; 2006; 54(2):164-72. PubMed ID: 16782359
[TBL] [Abstract][Full Text] [Related]
7. Tuning out of hERG.
Aronov AM
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
[TBL] [Abstract][Full Text] [Related]
8. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
Du F; Babcock JJ; Yu H; Zou B; Li M
PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
11. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
Seierstad M; Agrafiotis DK
Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
[TBL] [Abstract][Full Text] [Related]
12. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
13. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
Meyers KM; Méndez-Andino JL; Colson AO; Warshakoon NC; Wos JA; Mitchell MC; Hodge KM; Howard JM; Ackley DC; Holbert JK; Mittelstadt SW; Dowty ME; Obringer CM; Reizes O; Hu XE
Bioorg Med Chem Lett; 2007 Feb; 17(3):819-22. PubMed ID: 17107796
[TBL] [Abstract][Full Text] [Related]
14. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656.
Scholz EP; Zitron E; Kiesecker C; Thomas D; Kathöfer S; Kreuzer J; Bauer A; Katus HA; Remppis A; Karle CA; Greten J
Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):666-75. PubMed ID: 16926094
[TBL] [Abstract][Full Text] [Related]
15. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.
Meyers KM; Kim N; Méndez-Andino JL; Hu XE; Mumin RN; Klopfenstein SR; Wos JA; Mitchell MC; Paris JL; Ackley DC; Holbert JK; Mittelstadt SW; Reizes O
Bioorg Med Chem Lett; 2007 Feb; 17(3):814-8. PubMed ID: 17107791
[TBL] [Abstract][Full Text] [Related]
16. Lidoflazine is a high affinity blocker of the HERG K(+)channel.
Ridley JM; Dooley PC; Milnes JT; Witchel HJ; Hancox JC
J Mol Cell Cardiol; 2004 May; 36(5):701-5. PubMed ID: 15135665
[TBL] [Abstract][Full Text] [Related]
17. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
18. Why are most phospholipidosis inducers also hERG blockers?
Slavov S; Stoyanova-Slavova I; Li S; Zhao J; Huang R; Xia M; Beger R
Arch Toxicol; 2017 Dec; 91(12):3885-3895. PubMed ID: 28551711
[TBL] [Abstract][Full Text] [Related]
19. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
20. Indexing molecules for their hERG liability.
Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
